WO1997004099A3 - Papillomviren, mittel zu deren nachweis sowie zur therapie von durch sie verursachten erkrankungen - Google Patents

Papillomviren, mittel zu deren nachweis sowie zur therapie von durch sie verursachten erkrankungen Download PDF

Info

Publication number
WO1997004099A3
WO1997004099A3 PCT/DE1996/001369 DE9601369W WO9704099A3 WO 1997004099 A3 WO1997004099 A3 WO 1997004099A3 DE 9601369 W DE9601369 W DE 9601369W WO 9704099 A3 WO9704099 A3 WO 9704099A3
Authority
WO
WIPO (PCT)
Prior art keywords
papillomaviruses
viruses
agents
detecting
diseases caused
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/DE1996/001369
Other languages
English (en)
French (fr)
Other versions
WO1997004099A2 (de
Inventor
Vladimir Shamanin
Villiers-Zur Hausen Ethel-M De
Hausen Harald Zur
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Deutsches Krebsforschungszentrum DKFZ
Original Assignee
Deutsches Krebsforschungszentrum DKFZ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Deutsches Krebsforschungszentrum DKFZ filed Critical Deutsches Krebsforschungszentrum DKFZ
Priority to US09/000,266 priority Critical patent/US6322795B1/en
Priority to JP9506174A priority patent/JPH11512925A/ja
Priority to EP96928326A priority patent/EP0839199A1/de
Publication of WO1997004099A2 publication Critical patent/WO1997004099A2/de
Anticipated expiration legal-status Critical
Priority to US09/628,099 priority patent/US6368832B1/en
Publication of WO1997004099A3 publication Critical patent/WO1997004099A3/de
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Die Erfindung betrifft eine für ein Peptid eines Papillomvirus-Hauptcapsid-Proteins codierende DNA. Ferner betrifft die Erfindung ein eine solche DNA enthaltendes Papillomvirus-Genom. Des weiteren betrifft die Erfindung durch das Papillomvirus-Genom codierte Proteine und Virus-ähnliche Partikel sowie gegen sie gerichtete Antikörper und deren Verwendung in Diagnose, Therapie und Vakzinierung.
PCT/DE1996/001369 1995-07-19 1996-07-19 Papillomviren, mittel zu deren nachweis sowie zur therapie von durch sie verursachten erkrankungen Ceased WO1997004099A2 (de)

Priority Applications (4)

Application Number Priority Date Filing Date Title
US09/000,266 US6322795B1 (en) 1995-07-19 1996-07-19 Papilloma viruses, agents for detecting them and for treating diseases caused by such viruses
JP9506174A JPH11512925A (ja) 1995-07-19 1996-07-19 パピローマウイルス、その検出用製品及びそれにより生ずる疾病の治療用製品
EP96928326A EP0839199A1 (de) 1995-07-19 1996-07-19 Papillomviren, mittel zu deren nachweis sowie zur therapie von durch sie verursachten erkrankungen
US09/628,099 US6368832B1 (en) 1995-07-19 2000-05-25 Papilloma viruses, agents for detecting them and for treating diseases caused by such viruses

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19526386A DE19526386C1 (de) 1995-07-19 1995-07-19 Papillomviren, Mittel zu deren Nachweis sowie zur Therapie von durch sie verursachten Erkrankungen
DE19526386.3 1995-07-19

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US09/000,266 A-371-Of-International US6322795B1 (en) 1995-07-19 1996-07-19 Papilloma viruses, agents for detecting them and for treating diseases caused by such viruses
US09/628,099 Division US6368832B1 (en) 1995-07-19 2000-05-25 Papilloma viruses, agents for detecting them and for treating diseases caused by such viruses

Publications (2)

Publication Number Publication Date
WO1997004099A2 WO1997004099A2 (de) 1997-02-06
WO1997004099A3 true WO1997004099A3 (de) 2001-04-12

Family

ID=7767261

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DE1996/001369 Ceased WO1997004099A2 (de) 1995-07-19 1996-07-19 Papillomviren, mittel zu deren nachweis sowie zur therapie von durch sie verursachten erkrankungen

Country Status (5)

Country Link
US (4) US6322795B1 (de)
EP (1) EP0839199A1 (de)
JP (1) JPH11512925A (de)
DE (1) DE19526386C1 (de)
WO (1) WO1997004099A2 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19648962C1 (de) * 1996-11-26 1998-02-26 Deutsches Krebsforsch Papillomviren, Mittel zu deren Nachweis sowie zur Therapie von durch sie verursachten Erkrankungen
DE19712541C1 (de) * 1997-03-25 1998-11-05 Deutsches Krebsforsch Papillomviren, Mittel zu deren Nachweis sowie zur Therapie von durch sie verursachten Erkrankungen
DE19735118C1 (de) * 1997-08-13 1998-08-13 Deutsches Krebsforsch Papillomviren, Mittel zu deren Nachweis sowie zur Therapie von durch sie verursachten Erkrankungen
US7094541B2 (en) * 2001-08-31 2006-08-22 Gen-Probe Incorporated Assay for detection of human parvovirus B19 nucleic acid
KR101510065B1 (ko) 2005-06-08 2015-04-07 다나-파버 캔서 인스티튜트 인크. 예정 세포사 1(ｐｄ-1) 경로를 억제함으로써 지속 감염 및 암을 치료하기 위한 방법 및 조성물
CA2947292C (en) 2006-12-27 2019-07-23 Emory University Compositions and methods for the treatment of infections and tumors
EP2370593B1 (de) 2008-11-28 2016-03-30 Emory University Verfahren zur bestimmung der wirksamkeit von pd-1 antagonisten
CA2799205A1 (en) 2010-05-25 2011-12-01 Qiagen Gaithersburg, Inc. Fast results hybrid capture assay and associated strategically-truncated probes
JP2019512271A (ja) 2016-03-21 2019-05-16 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド Ｔ細胞疲弊状態特異的遺伝子発現調節因子およびその使用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0301289A1 (de) * 1987-07-11 1989-02-01 BEHRINGWERKE Aktiengesellschaft Humaner Papillomvirus Typ 41
EP0370625A1 (de) * 1988-10-26 1990-05-30 Georgetown University DNS-Sequenzen des menschlichen Papillomavirus Typ 52 und Verfahren zu ihrer Verwendung
WO1994005792A1 (en) * 1992-09-03 1994-03-17 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Self-assembling recombinant papillomavirus capsid proteins
DE4415743A1 (de) * 1994-05-04 1995-11-09 Deutsches Krebsforsch Papillomviren, Mittel zu deren Nachweis sowie zur Therapie von durch sie verursachten Erkrankungen

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0301289A1 (de) * 1987-07-11 1989-02-01 BEHRINGWERKE Aktiengesellschaft Humaner Papillomvirus Typ 41
EP0370625A1 (de) * 1988-10-26 1990-05-30 Georgetown University DNS-Sequenzen des menschlichen Papillomavirus Typ 52 und Verfahren zu ihrer Verwendung
WO1994005792A1 (en) * 1992-09-03 1994-03-17 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Self-assembling recombinant papillomavirus capsid proteins
DE4415743A1 (de) * 1994-05-04 1995-11-09 Deutsches Krebsforsch Papillomviren, Mittel zu deren Nachweis sowie zur Therapie von durch sie verursachten Erkrankungen

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BROWNE H.M. ET AL.: "Analysis of the L1 gene product of human Papillomavirus Type 16 by expression in a Vaccinia Virus recombinant.", J. GEN. VIROLOGY, vol. 69, 1988, pages 1263 - 1273, XP002023586 *
EGAWA K. ET AL.: "Two novel types of Human Papillomavirus, HPV 63 and HPV 65: Comparisons of their clinical and histological features and DNA sequences to other HPV types.", VIROLOGY, vol. 194, 1993, pages 789 - 799, XP002023584 *
JARRETT W.F.H. ET AL.: "Studies on vaccination against Papillomaviruses:Prophylactic and therapeutic vaccination with recombinant structural protein.", VIROLOGY, vol. 184, 1991, pages 33 - 42, XP002023588 *
SHAMANIN ET AL.: "Specific types of Human Papillomavirus found in benign proliferations and carcinomas of the skin in immunosuppressed patients.", CANCER RESEARCH, vol. 54, 1 September 1994 (1994-09-01), pages 4610 - 4613, XP002023585 *
SHAMANIN V. ET AL.: "Human papillomavirus infections in nonmelanoma skin cancer from renal transplant recipients and nonimmunosuppressed patients.", JOURNAL OF THE NATIONAL CANCER INSTITUTE, vol. 88, no. 12, 19 June 1996 (1996-06-19), pages 802 - 811, XP000616318 *

Also Published As

Publication number Publication date
US6322795B1 (en) 2001-11-27
US6562597B2 (en) 2003-05-13
US6555345B2 (en) 2003-04-29
US6368832B1 (en) 2002-04-09
US20020110866A1 (en) 2002-08-15
EP0839199A1 (de) 1998-05-06
US20020110865A1 (en) 2002-08-15
DE19526386C1 (de) 1997-01-02
JPH11512925A (ja) 1999-11-09
WO1997004099A2 (de) 1997-02-06

Similar Documents

Publication Publication Date Title
ATE288489T1 (de) Vp-antigene des jc-virus
LU91391I2 (fr) "La combinaison de particules viroïdes de la protéine L1 recombinante du papillomavirus humain de types 16 et 18" Cervarix
EP1016418A3 (de) Zusammensetzung enthaltend ein rekombinantes Virus, welches ein Antigen exprimiert und ein rekombinantes Virus, welches ein immunstimulatorisches Molekül exprimiert
AU6117696A (en) Nucleic acid respiratory syncytial virus vaccines
WO1996011279A3 (en) Enhanced immune response by introduction of cytokine gene and/or costimulatory molecule b7 gene in a recombinant virus expressing system
EP1847549A3 (de) Polyproteinkonstrukte des Papillomavirus
WO1995026411A3 (en) Composition and methods for creating syngeneic recombinant virus-producing cells
ATE91630T1 (de) Pharmazeutische zusammensetzung zur verhuetung oder heilung von durch den papillomavirus induzierten tumoren.
HUP9801334A2 (hu) A 18-as típusú humán papillomavírust kódoló DNS
EP0868522A4 (de) Rekombinantes pockenvirus der infektiösen peritonitis der katze, zusammensetzungen dessen und methoden zur herstellung und verwendung
AU4149699A (en) Use of inactivated immunosuppressive and/or angiogenic immunogenic proteins, preparation method and pharmaceutical or vaccine uses
WO1998023752A3 (de) Papillomviren, mittel zu deren nachweis sowie zur therapie von durch sie verursachten erkrankungen
WO1999009177A3 (de) Papillomviren, mittel zu deren nachweis sowie zur therapie von durch sie verursachten erkrankungen
WO1998042847A3 (de) Papillomvirus-hauptcapsid-proteins und deren verwendung in diagnose, therapie und vakzinierung
WO1996040764A3 (en) Nucleotide and amino acid sequences of hypervariable region 1 of the envelope 2 gene of hepatitis c virus
WO2000014112A3 (de) Papillomviren, mittel zu deren nachweis sowie zur therapie von durch sie verursachten erkrankungen
WO2002047720A3 (en) Treatment and prevention of ebv infection and ebv-associated disorders
AU5153196A (en) Diagnostic and therapeutic system for Crohn's Disease and colitia ulcerosa
FR2792639B1 (fr) Nouveaux immunogenes anti-vih (toxoides), nouveaux procedes de preparation et application a la prevention et au traitement du sida
WO2000024876A3 (en) Spumavirus isolated from humans
MX9709525A (es) Vacunas de virus sincicial respiratorio de acido nucleico.
MX9709390A (es) Cistatina e humana.
ATE393215T1 (de) Chimäre virus-ähnliche partikel bzw. chimäre capsomere von bpv (bovine papilloma virus)

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): JP US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref country code: JP

Ref document number: 1997 506174

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1996928326

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1996928326

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 09000266

Country of ref document: US

AK Designated states

Kind code of ref document: A3

Designated state(s): JP US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

WWR Wipo information: refused in national office

Ref document number: 1996928326

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1996928326

Country of ref document: EP